-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FSD Pharma (NASDAQ:HUGE) Shares Up 2.3%
FSD Pharma (NASDAQ:HUGE) Shares Up 2.3%
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating)'s stock price shot up 2.3% on Monday . The stock traded as high as $0.89 and last traded at $0.89. 1,995 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 111,853 shares. The stock had previously closed at $0.87.
FSD Pharma Price Performance
The company's fifty day moving average is $0.93 and its two-hundred day moving average is $0.90.
Get FSD Pharma alerts:Institutional Investors Weigh In On FSD Pharma
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its position in FSD Pharma by 145.1% in the 1st quarter. Renaissance Technologies LLC now owns 32,600 shares of the company's stock worth $28,000 after purchasing an additional 19,300 shares in the last quarter. AdvisorShares Investments LLC purchased a new stake in FSD Pharma in the 1st quarter worth approximately $148,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in FSD Pharma in the 4th quarter worth approximately $1,007,000. Hedge funds and other institutional investors own 1.26% of the company's stock.
About FSD Pharma
(Get Rating)FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Featured Articles
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- What Does an Inverted Yield Curve Mean For You?
- SPY vs. QQQ: Which ETF Wins in 2022?
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
FSD Pharma Inc. (NASDAQ:HUGE – Get Rating)'s stock price shot up 2.3% on Monday . The stock traded as high as $0.89 and last traded at $0.89. 1,995 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 111,853 shares. The stock had previously closed at $0.87.
纳斯达克网站FSD Pharma Inc.的股价周一飙升2.3%，盘中一度涨至0.89美元的高点，尾盘报0.89美元。午盘时分，有1,995股股票易手，较111,853股的平均成交量下跌98%。该股此前收盘报0.87美元。
FSD Pharma Price Performance
消防处药价表现
The company's fifty day moving average is $0.93 and its two-hundred day moving average is $0.90.
该公司的50日移动均线切入位在0.93美元，200日移动均线切入位在0.90美元。
Institutional Investors Weigh In On FSD Pharma
机构投资者参与FSD Pharma
Hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC boosted its position in FSD Pharma by 145.1% in the 1st quarter. Renaissance Technologies LLC now owns 32,600 shares of the company's stock worth $28,000 after purchasing an additional 19,300 shares in the last quarter. AdvisorShares Investments LLC purchased a new stake in FSD Pharma in the 1st quarter worth approximately $148,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in FSD Pharma in the 4th quarter worth approximately $1,007,000. Hedge funds and other institutional investors own 1.26% of the company's stock.
对冲基金最近买卖了该股的股票。复兴科技有限公司在第一季度将其在FSD Pharma的头寸增加了145.1%。复兴科技有限责任公司在上个季度又购买了19,300股后，现在拥有32,600股该公司股票，价值28,000美元。AdvisorShares Investments LLC在第一季度购买了FSD Pharma的新股份，价值约14.8万美元。最后，未来资产全球投资有限公司在第四季度购买了FSD Pharma公司价值约1007,000美元的新股份。对冲基金和其他机构投资者持有该公司1.26%的股票。
About FSD Pharma
关于消防处药业
FSD Pharma Inc, through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
FSD Pharma Inc.通过其子公司作为一家制药研发公司运营。它的主要候选药物包括正在进行治疗新冠肺炎疾病的第二阶段临床试验的FSD-201。该公司还专注于Lucid-Topch，一种被发现用于潜在治疗抑郁症等神经精神疾病的精神活性分子；以及Lucid-MS，一种获得专利的新化学实体，被证明在临床前模型中可以防止和逆转髓鞘降解，这是多发性硬化症的潜在机制。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on FSD Pharma (HUGE)
- What Does an Inverted Yield Curve Mean For You?
- SPY vs. QQQ: Which ETF Wins in 2022?
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- 免费获取StockNews.com关于FSD Pharma的研究报告(Heavy)
- 收益率曲线倒置对你意味着什么？
- 标普500ETF VS QQQ：2022年哪只ETF胜出？
- 随着管理层重组，股市能否迅速反弹？
- MarketBeat：回顾中的一周8/29-9/2
- 霍梅尔在这些水平上看起来很便宜
Receive News & Ratings for FSD Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FSD Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
接受《消防局医药日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对FSD Pharma和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧